Novartis' Late Bloomer Entresto Leads Take-Off Of Heart Failure Market
Executive Summary
Market snapshot: Growth of Novartis' Entresto along with greater use of SGLT-2 inhibitors and the entry of new branded drugs will boost sales of drugs for chronic heart failure from $4.6bn in 2017 to $10.1bn in 2026, despite wide availability of generics, according to a new Datamonitor forecast.
You may also be interested in...
Amgen’s Growth Story Relies Mainly On Continuing Plot Lines
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
Cytokinetics Sees Omecamtiv Potential In Certain Heart Failure Patients
Detailed data for omecamtiv mecarbil at AHA show a slim overall benefit, but Cytokinetics highlighted its effects in sicker patients and investigators emphasized the drug’s impact on reduced hospitalizations.
Real World Data Helping To Drive Rise Of Novartis' Entresto
Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.